Study of CHS-114 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05635643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Study identification
- NCT ID
- NCT05635643
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 87 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2022 (Actual)
- Primary completion
- Sep 30, 2026 (Estimated)
- Completion
- Jan 1, 2027 (Estimated)
- Last update posted
- Aug 12, 2026
2022 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Center | Palo Alto | California | 94305 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30308 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| University of Michigan | Ann Arbor | Michigan | 48104 | — |
| Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | — |
| START- San Antonio | San Antonio | Texas | 78229 | — |
| START Mountain | West Valley City | Utah | 84119 | — |
| University of Washington/Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05635643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05635643 live on ClinicalTrials.gov.